drugset / Trial / NCT05313035
Safety and Immunogenicity Study of COVID-19 Protein Subunit Recombinant Vaccine
Phase 2/3
Completed
360 enrolled
PT Bio Farma
Andalas University · collabFaculty of Medicine, Diponegoro University, Semarang · collabFaculty of Medicine, Universitas Hassanudin, Makassar · collabIndonesia University · collab
RandomizedParallel-groupDouble-blindTreatment
Summary
This trial is observer-blind, comparative, randomized, placebo-controlled phase 2 study. The population is healthy subjects aged 18 and above
Timeline
- Start
- 2022-04-13
- Primary completion
- 2022-07-22
- Completion
- 2023-02-28
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | SARS-CoV-2 Protein Subunit Recombinant Vaccine | Vaccine | 0.5 ml | — |